Department of Medicine, New York University School of Medicine, 550 First Avenue, NBV16N1, New York, NY 10016, USA.
Nat Rev Rheumatol. 2010 Mar;6(3):175-8. doi: 10.1038/nrrheum.2010.5.
Methotrexate remains a cornerstone in the treatment of rheumatoid arthritis and other rheumatic diseases. Folate antagonism is known to contribute to the antiproliferative effects that are important in the action of methotrexate against malignant diseases, but concomitant administration of folic or folinic acid does not diminish the anti-inflammatory potential of this agent, which suggests that other mechanisms of action might be operative. Although no single mechanism is sufficient to account for all the anti-inflammatory activities of methotrexate, the release of adenosine from cells has been demonstrated both in vitro and in vivo. Methotrexate might also confer anti-inflammatory properties through the inhibition of polyamines. The biological effects on inflammation associated with adenosine release have provided insight into how methotrexate exerts its effects against inflammatory diseases and at the same time causes some of its well-known adverse effects. These activities contribute to the complex and multifaceted mechanisms that make methotrexate efficacious in the treatment of inflammatory disorders.
甲氨蝶呤仍然是治疗类风湿关节炎和其他风湿性疾病的基石。已知叶酸拮抗作用有助于甲氨蝶呤对抗恶性疾病的增殖作用,但同时给予叶酸或亚叶酸并不能降低该药物的抗炎潜力,这表明可能存在其他作用机制。虽然没有单一的机制足以解释甲氨蝶呤的所有抗炎活性,但已经在体外和体内证明了细胞内腺苷的释放。甲氨蝶呤也可能通过抑制多胺来发挥抗炎作用。与腺苷释放相关的对炎症的生物学效应提供了对甲氨蝶呤如何发挥其对炎症性疾病的作用的深入了解,同时也导致了其一些众所周知的不良反应。这些活性有助于解释甲氨蝶呤在治疗炎症性疾病时发挥疗效的复杂和多方面的机制。